Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mediwound Ltd Ord Sh (NQ: MDWD )

10.92 UNCHANGED
Streaming Delayed Price Updated: 3:56 PM EDT, Mar 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 10.92
Bid (Size) 9.900 (1)
Ask (Size) 13.38 (1)
Prev. Close 10.92
Today's Range 10.92 - 10.92
52wk Range 8.050 - 17.08
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
5 Analysts Have This to Say About MediWound
 
Via Benzinga
MediWound Reports Fourth Quarter and Full Year 2022 Financial Results and Company Update
From MediWound Ltd.
Via Globe NewsWire

Performance

YTD
-17.83%
-17.83%
1 Month
-7.93%
-7.93%
3 Month
+16.42%
+16.42%
6 Month
-12.85%
-12.85%
1 Year
-19.17%
-19.17%

More News

Read More
MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer
From MediWound Ltd.
Via Globe NewsWire
Preview: MediWound's Earnings
Via Benzinga
MediWound Expands its Global Leadership Team to Help Drive Company’s Future Growth
From MediWound Ltd.
Via Globe NewsWire
Cowen & Co. Maintains Outperform Rating for MediWound: Here's What You Need To Know
Via Benzinga
FDA Approves MediWound's NexoBrid For Burn Treatment
Via Benzinga
MediWound to Report Fourth Quarter and Year-End 2022 Financial Results
From MediWound Ltd.
Via Globe NewsWire
MediWound to Present Corporate Highlights at Upcoming Investor Conferences
From MediWound Ltd.
Via Globe NewsWire
MediWound Announces Closing of $27.5 Million Registered Direct Offering of Ordinary Shares
From MediWound Ltd.
Via Globe NewsWire
MediWound Announces $27.5 Million Registered Direct Offering of Ordinary Shares Priced At-The-Market
From MediWound Ltd.
Via Globe NewsWire
Starbucks To Rally 11%? Here Are 10 Other Analyst Forecasts For Wednesday
Via Benzinga
MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
From MediWound Ltd.
Via Globe NewsWire
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Via Benzinga
MediWound Expands NexoBrid’s Global Presence with Marketing Approval in Japan
From MediWound Ltd.
Via Globe NewsWire
MediWound Strengthens European Presence of NexoBrid®
From MediWound Ltd.
Via Globe NewsWire
MediWound Announces Positive Results in U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
From MediWound Ltd.
Via Globe NewsWire
MediWound Expands Global Presence as NexoBrid® Gains Approval in India
From MediWound Ltd.
Via Globe NewsWire
MediWound Announces a 1-for-7 Reverse Share Split
From MediWound Ltd.
Via Globe NewsWire
MediWound to Report Third Quarter 2022 Financial Results
From MediWound Ltd.
Via Globe NewsWire
Earnings Scheduled For November 15, 2022
Via Benzinga
MediWound Announces Formation of Strategic Advisory Board
From MediWound Ltd.
Via Globe NewsWire
MediWound's EscharEx® Featured in Oral and Poster Presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022
From MediWound Ltd.
Via Globe NewsWire
MediWound Announces Closing of the Concurrent Registered Direct and Private Placement Offerings
From MediWound Ltd.
Via Globe NewsWire
Why Avenue Therapeutics Shares Surged Around 106%; Here Are 87 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.